|
|||||
|
|
Therapeutic potential of RAS prenylation pharmacological inhibitors in the treatment of breast cancer,recent progress,and prospective |
|
| Authors: | Atena Soleimani Mostafa Amirinejad Sara Rahsepar Fatemeh Vazirian Afsane Bahrami Gordon A. Ferns Majid Khazaei Amir Avan Seyed Mahdi Hassanian |
| Affiliation: | 1. Department of Clinical Biochemistry, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran Student Research Committee, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran;2. School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran Student Research Committee, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran;3. School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran;4. Cellular and Molecular Research Center, Birjand University of Medical Sciences, Birjand, Iran;5. Division of Medical Education, Brighton & Sussex Medical School, Brighton, UK;6. Department of Medical Physiology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran Metabolic Syndrome Research Center, Mashhad University of Medical Sciences, Mashhad, Iran;7. Metabolic Syndrome Research Center, Mashhad University of Medical Sciences, Mashhad, Iran;8. Department of Clinical Biochemistry, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran |
| Abstract: | Breast cancer is one of the most prevalent malignancies among women around the world. RAS proteins require posttranslational modifications, including protein prenylation for proper membrane localization and signaling. Regulation of RAS signaling via specific and novel pharmacological inhibitors is a potentially novel therapeutic approach in breast cancer therapy. This review summarizes the recent knowledge about the clinical value of RAS prenylation pharmacological inhibitors in breast cancer treatment. |
| Keywords: | breast cancer (BC) farnesyltransferase inhibitors (FTI) geranylgeranyl transferase (GGTase) inhibitors RAS prenylation |